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Abstract 
Immunotherapies have significant potential for implementation towards personalized 
medicine through avenues such as vaccine, gene, and cancer applications. Dendritic cells are a 
major contributor in the immune system, functioning as antigen-presenting cells that aid in 
orchestrating the immune response towards pathogenic activators. Manipulation of these cells 
can allow for the optimization of immune responses, which can be achieved through tissue 
engineering and modulation via gold nanoparticles. This study seeks to provide a basis for 
elucidating the secretory responses of immature dendritic cells as they progress through 
maturation following treatment with modified gold nanoparticles. Additionally, findings are 
presented on the manipulation of dendritic cells with a variety of treatments such as PEGylation 
and thiolation to understand resulting effects on IL-10 expression. Biomaterial-based matrices 
are additionally investigated for their roles in dendritic cell viability and functionality – results of 
variation in weight percentage of hydrogels, used for dendritic cell encapsulation, will be shown. 
With some notable exceptions, such as IL-4, the majority of cytokine and chemokine expressions 
in experimental cell groups compared to baseline immature dendritic cell expression levels 
decreased. Future studies should continue to characterize and solidify this response, both with 
regard to modulation in hydrogels and gold nanoparticles. These studies can aid in paving the 








 Within the field of immunotherapeutic techniques, an increasingly investigated method 
for augmenting the immune response is the manipulation of dendritic cells with biomaterials. 
One such biomaterial that can be used is gold nanoparticles, which have the ability to target 
dendritic cell surface receptors in order to induce a phenotypic, observable response that 
orchestrates greater immune activity. Researchers are currently aiming to understand how 
characteristics of gold nanoparticles can assist in determining the phenotypic response of the 
cells. If understood, this knowledge could be used to engineer a specific and personalized 
immune response. Furthermore, researchers are investigating how these cellular responses can 
change due to variation in the nanoparticles’ parameters. Some research has shown that as gold 
nanoparticles interact with dendritic cells, they can initiate the maturation process of immature 
dendritic cells to have them express activated or tolerogenic phenotypes.1  
 This maturation process is an integral component to the immune response of the body. 
Maturation of a dendritic cell occurs upon exposure and subsequent phagocytosis of antigens, 
followed by the production of corresponding peptides that are expressed on the cell surface. 
Dendritic cells additionally maintain an immune tolerance towards self-antigens. Studies with 
gold nanoparticle methodology have shown promising results thus far in inducing maturation, 
with researchers confirming the efficacy of the nanoparticles as an adjuvant to vaccine delivery 
and for eliciting an anti-tumor response in cancer patients.2,3 However, as this treatment gains 
more potential for clinical application, the potential cytotoxicity of the nanoparticles and their 
safety in patients must also be considered. 
The immune responses by dendritic cells in the body are mediated through varying 
conditions in the treatment groups involving gold nanoparticle application. This response by the 
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dendritic cells is shown through the release of corresponding cytokines and chemokines into the 
cell environment.4 Currently, the cytokine and chemokine expression of dendritic cells upon 
treatment with various coatings is not fully established. By identifying what the supernatant is 
comprised of as a result of nanoparticle application with varying coatings and concentrations, 
researchers can better understand what specific response is being triggered and what phenotype 
is being expressed within the dendritic cells, thus giving greater ability to assess their potential 
risks. 
In addition to this, biomaterials have been shown to modulate dendritic cell viability and 
functionality.5 Research has been done to explore the potential of various materials to activate 
dendritic cells, as well as their mechanisms of maturation.6,7 Further work, however, still needs 
to be done in the identification of the structural components of biomaterial-based matrices that 
support non-activated or tolerogenic dendritic cells. By investigating the structure and function 
relationships that govern hydrogel matrices and dendritic cell interactions, this knowledge can 
direct the design of hydrogels to support dendritic cells. Further biochemical modifications can 
be introduced to the matrices that can be used in the improvement of the scaffold’s ability to 
maintain encapsulated cell viability and tolerogenic functionality.8 
 In this study, assays will be conducted to identify the cytokine and chemokine profile that 
is released from treated dendritic cells. The goal of this experiment is to more clearly understand 
the cellular immune response elicited by different treatment groups of coatings and 
concentrations. During the preliminary treatment steps, dendritic cells are treated with three 
different conditions of nanoparticle groups: bare, serum-coated, and polyethylene glycol (PEG) 
coated. The PEG groups contain PEG-2K (short chain PEG) and PEG-5K (long chain PEG) 
variations. Each of these treatments are administered at concentrations of 0.1 pM, 1.0 pM, and 10 
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pM, for a total of twelve treatment groups. Following treatment by these groups, the cytokine 
and chemokine release response can be characterized via Luminex analysis (Millipore). This is 
done in order to study the levels of the pro- and anti-inflammatory cytokines IL-1β, IL-1Ra, 
MIP-1α, TNF-α, and IL-10 present in the dendritic cell response. These cytokines are detectable 
upon cell contact with biomaterials and indicate the dendritic cell phenotype that is being 
expressed. Ultimately, these assays will help determine how the immune system responds to gold 
nanoparticles and will inform nanoparticle design criteria for immunotherapeutic application in 
patients. Additionally, secretory profiles of dendritic cells treated with various modifications, 

















The immune system response to a pathogen is twofold, including both the innate and 
adaptive immune responses. The two aspects of response work in conjunction with one another 
but differ in their approach towards establishing immunity for the body. The innate response 
provides an immediate immune response, but it does not provide a tailored mechanism to the 
antigens being defended against. Examples of this include inflammation and non-specific cellular 
responses. In contrast, the adaptive immune response does not act immediately; instead, it takes 
several weeks to develop, but provides a tailored response to the antigens present. This response 
functions through T and B lymphocytes and retains memory of the response towards a specific 
antigen in order to elicit a quicker reaction upon subsequent exposure. Both of these responses 
are mediated in the body through the dendritic cells of the immune system.9 
 Dendritic cells work to conduct both the innate and adaptive immune response in the 
body by activating T-cells.10 The dendritic cells function first as antigen-capturing cells, then as 
antigen-presenting cells, meaning they capture antigens through phagocytosis, perform internal 
processing, and then present the resulting peptide of the antigen on their cell surface. Dendritic 
cells are a product of monocytes, a type of differentiated cell from bone marrow.11 When an 
innate immune response is initiated, monocytes congregate at the site of inflammation and 
further develop into immature dendritic cells. Upon producing antigenic peptides after 
phagocytizing antigens and expressing them on their surface, the phenotype of the immature 
dendritic cell is changed to a mature dendritic cell.12  
 Nanoparticles are defined as particles ranging in size from 1-100nm; their characteristics 
vary broadly in size, shape, material, and coating. They are used in medicine to carry and deliver 
drugs to specific targets with a controlled release and specified targeting due to their low cell 
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toxicity. Within immunotherapy specifically, gold nanoparticles have shown to be promising for 
dendritic cell manipulation in order to augment the immune response. Gold nanoparticles are 
favorable in this application due to their inertness, solubility in water, and low toxicity in cells.13 
These nanoparticles can be used to heighten the activity of dendritic cells in stimulating specific 
T-cell responses, which has shown potential in developing strategies for vaccine, gene, and 
cancer therapies.14  
 However, some questions remain in regard to the potential cytotoxicity of the 
nanoparticles. As the characteristics of the gold nanoparticles are varied and administered to 
dendritic cells, the cells release corresponding cytokines and chemokines into the cell 
environment.15 Studies have shown that as particle size increases, efficiency of particle uptake by 
dendritic cells decreases. The nanoparticles must be optimized to balance the ability to carry 
what they are loaded with but cannot be too large to be eliminated before they have a chance to 
interact with dendritic cells.16 Small gold nanoparticles (diameter of 3 nm) have been shown to 
be noncytotoxic and nonimmunogenic, as the secretion of proinflammatory cytokines TNF-α and 
IL-1β were not observed.17 Another study showed results where smaller gold nanoparticles sizes, 
such as 0.8 nm, were associated with increased expression of proinflammatory cytokines IL-1, 
IL-6 and TNF-α, as well as higher cytotoxicity.18 Noncytotoxicity has been shown for dendritic 
cells with the use of gold nanoparticles of larger size (10 nm and 60 nm in diameter) even at high 
concentrations.18,19 
Additionally, the concentration of gold nanoparticles present also plays a role in uptake 
and cytotoxicity. Higher gold nanoparticle concentrations have shown to increase rates of 
toxicity to cells, so in addition to size and coating, the amount per volume of nanoparticle present 
must also be investigated and optimized for greatest uptake and minimal cell toxicity.20 This 
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occurs because with excess nanoparticles beyond what is effective, there is an increased chance 
of the nanoparticles creating nanopores within the cell that ultimately can engender interference 
with normal cellular function and damage the cell. The threshold at which gold nanoparticle 
concentrations with particular specifications in size or coating result in cytotoxicity is not 
established and needs further investigation. 
Finally, the coatings of nanoparticles can affect their uptake. Serum-coating the gold 
nanoparticles or attaching a long chain polymer, such as polyethylene glycol (PEG), has been 
shown to decrease phagocytic uptake of nanoparticles in order to increase their circulation time. 
This increases the efficacy of the nanoparticles in situations where their phagocytosis can cause 
insufficient exposure to the site being targeted.21,22 Conversely, coatings can be used to enhance 
phagocytosis, where the uptake of the gold nanoparticles increases their target efficiency. 
Coatings can also be used to induce a specific phenotype in the dendritic cell, resulting in either 
immature, mature, or tolerogenic cells, and consequently engineering a specific immune 
response. However, strong correlations between uptake and maturation as a result of surface 
chemistries have not yet been established. Variations in nanoparticle coating not only affords 
different chemical properties to nanoparticles – different densities of the same coating can 
additionally effect change in nanoparticle modulation. For example, one study used increasing 
PEG-coating densities with gold nanoparticles and found that macrophage uptake efficiency was 
high and serum-dependent at low PEG densities, while less efficient and serum-independent at 
high PEG densities.23 Additionally, selecting nanoparticle coatings has important implications in 
the formation of a gold nanoparticle-protein corona. This corona is a dynamic biopolymer layer 
serving as the first nano-bio interface, thus determining the interactions of gold nanoparticles 
with living cells.24 As many as sixty-nine plasma proteins are able to bind to the surface of a gold 
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nanoparticle,25,26 and these proteins largely pertain to the fate of a gold nanoparticle in the body 
through biodistribution, cellular uptake and clearance efficiency, as well as immunological 
properties. As shown by the literature, the cytokine and chemokine response from dendritic cells 
is not fully established, thus demonstrating the need for more studies to inform how particle 
coating, in addition to concentration, modulates cellular interactions. 
In this experiment, the supernatant will be analyzed once obtained from the filtration of 
cells from the initial culture using a filter plate. By understanding what comprises the 
supernatant resulting from nanoparticle application, researchers can better understand what exact 
response is being triggered within the dendritic cells and assess their potential risks. This study 
uses Luminex analysis to analyze the supernatant and characterize dendritic cell response by 
investigating the levels of the pro- and anti-inflammatory cytokines IL-1β, IL-1Ra, MIP-1α, 
TNF-α, IL-10, IFN-γ, IL-12p70, MCP-1, and RANTES. The goal is to more clearly elucidate the 
effect of gold nanoparticle coating and concentration on dendritic cell response, paving the way 
for gold nanoparticles’ optimization in immunotherapy. 
Biomaterials have additionally been shown to modulate dendritic cell viability and 
functionality.5 The potential of various materials to activate dendritic cells, as well as their 
mechanisms of maturation, is currently being researched.6,7 By elucidating the qualities and 
benefits of a biomaterial-based scaffold that can support the functionality and induced outcomes 
by transferred, antigen-specific, tolerogenic dendritic cells, this knowledge can be applied to 
dendritic cell therapies in humans. The relationships that govern hydrogel matrices and dendritic 
cell interactions can be used in directing the design of hydrogels to support dendritic cells. Using 
a murine model provides for an anatomically relevant and scalable design. The project uses a 
PEG-4MAL hydrogel which is functionalized with bioactive ligands as a delivery scaffold for 
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tolerized dendritic cells. This can be used to ameliorate experimental autoimmune 
encephalomyelitis (EAE), as well as diseases such as multiple sclerosis (MS). Dendritic cells 
which are treated with tolerizing agents and antigen result in antigen-specific 
immunosuppressive dendritic cells. This function by conditioning T cells towards tolerance. 
Cells delivered subcutaneously or intravenously incur unwanted effects and distribution, so in 
developing an injectable hydrogel scaffold, viability and localization of delivered dendritic cells 
can be improved.27,28 Secretory profiles of immature dendritic cells will be analyzed following a 
variety of treatment methods, as well as encapsulation within modified hydrogels. These serve to 
illustrate the effects on IL-10 expression following modification, as well as the impact caused on 















Methods and Materials 
 This experiment is conducted through a Luminex assay in order to study the levels of the 
pro- and anti-inflammatory cytokines IL-1β, IL-1Ra, MIP-1α, TNF-α, and IL-10 present in the 
dendritic cell response. Initially, an assay must be conducted in order to obtain the linear range 
for the cytokines and chemokines to be investigated, which relates amount loaded to instrument 
fluorescent readout. This allows for the determination of the optimal concentrations that the 
supernatant should be diluted to for testing, so that ranges can be observed prior to saturation. 
After the linear range is identified, each treatment group (bare, serum-coated, PEG-2K coated, 
PEG-5K coated) can have an assay conducted at each concentration (0.1 pM, 1.0 pM, 10 pM). 
The cytokines specified are detectable upon cell contact with biomaterials and indicate the 
dendritic cell phenotype that is being expressed. 
 
Materials  
Necessary materials are included in Milliplex kit HCYTOMAG-60K. Materials that are 
required but not provided in Milliplex kit include reagents including Luminex sheath fluid or 
Luminex drive fluid as used for machine protocol. 
Reagents Supplied Volume Quantity 
Human Cytokine / Chemokine Standard lyophilized 1 vial 
Human Cytokine Quality Controls 1 and 2 lyophilized 2 vials 
Serum Matrix (Contains 0.08% Sodium Azide) lyophilized 1 vial (serum and plasma 
sample only) 
Set of one 96-Well Plates with 2 Sealers  1 plates 
2 sealers 
Assay Buffer 30 mL 1 bottle 
10X Wash Buffer 
Note: Contains 0.05% Proclin 
60mL 1 bottle 
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Cytokine Detection Antibodies 3.2 mL 1 bottle 
Streptavidin-Phycoerythrin 3.2 mL 1 bottle 
Bead Diluent 
(not provided with premixed panel) 
3.5 mL 1 bottle 
Mixing Bottle 
(not provided with premixed panel) 
             1 bottle 
 
For instrumentation, materials needed include the following: adjustable pipettes with tips 
capable of delivering 25 μL to 1000 μL, multichannel pipettes capable of delivering 5 μL to 50 
μL or 25 μL to 200 μL, reagent reservoirs, polypropylene microfuge tubes, absorbent pads, 
laboratory vortex mixer, sonicator, and titer plate shaker. Luminex 200, HTS (High Throughput 
Screening), FLEXMAP 3D®, or MAGPIX® with xPONENT® software by Luminex 
Corporation will also be used, as well as an automatic plate washer for magnetic beads or 
handheld magnetic separation block. 
Methods 
Results are read on MAGPIX software. Following sample collection of cells from initial 
murine or human cell culture done in lab, the cells are filtered out using a filter plate. 25 uL of 
supernatant from each of the below wells is then transferred. to each new corresponding sample 
well for cytokine assay (pictured below for reference). Mix supernatant well by vortexing and 
centrifuging prior to use in the assay to remove particulates. Following this, add a maximum of 
25 μL per well of neat or diluted serum. All samples must be stored in polypropylene tubes. Do 




Figure 1. Plate layout of initial gold nanoparticle and dendritic cell treatments in 96-well plate. 
Gold nanoparticle concentrations of 0.1 pM, 1.0 pM, and 10 pM were added to dendritic cells in 
individual wells for all gold nanoparticle treatment groups (bare, serum-coated, PEG-2K coated, 
and PEG-5K coated). Antibody staining was added to three wells of six wells per treatment, and 

























Figure 2. Plate layout for use in 
Luminex cytokine assay of 
uncoated, serum coated, and PEG 
5K coated nanoparticles. 
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Preparation of Reagents for Immunoassay 
In preparing the reagents for immune assay for individual bead vials, sonicate each 
antibody-bead vial for 30 seconds. Following this, vortex for 1 minute. Add 60 μL from each 
antibody bead vial (5 vials) to the mixing bottle and bring final volume to 3.0 mL with Bead 
Diluent by adding 2.7 mL. Vortex the mixed beads well using 5 cytokine antibody-immobilized 
beads – add 60 μL from each of the 5 bead sets to the mixing bottle. Then, add 2.7 mL Bead 
Diluent. To prepare quality controls, reconstitute Quality Control 1 and Quality Control 2 with 
250 μL deionized water. Invert the vial several times, vortex, and allow the vial to sit for 5-10 
minutes. Following this, transfer the controls to appropriately labeled polypropylene microfuge 
tubes 
To prepare wash buffers, bring the 10X Wash Buffer to room temperature. Mix to bring 
salts into solution, and dilute 60 mL to 10X Wash Buffer with 540 mL deionized water. 
Preparation of Human Cytokine Standard requires the following before use: reconstitution of the 
Human Cytokine Standard with 250 μL deionized water – this gives a 10,000 pg/mL 
concentration of standard for all analytes. Then invert the vial several times, vortex for 10 
seconds, and let stand for 5-10 minutes. Then transfer the standard to an appropriately labeled 
polypropylene microfuge tube and use as the 10,000 pg/mL standard. To prepare the working 
standards, label five polypropylene microfuge tubes 2,000, 400, 80, 16, and 3.2 pg/mL. Then add 
200 μL of Assay Buffer to each. Prepare serial dilutions by adding 50 μL of the 10,000 pg/mL 
reconstituted standard to the 2,000 pg/mL tube and mix well by vortexing. Transfer 50 μL of the 
2,000 pg/mL standard to the 400 pg/mL tube and mix well by vortexing. Transfer 50 μL of the 
400 pg/mL standard to the 80 pg/mL tube and mix well by vortexing. Transfer 50 μL of the 80 
pg/mL standard to 16 pg/mL tube and mix well by vortexing. Finally, transfer 50 μL of the 16 
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pg/mL standard to the 3.2 pg/mL tube and mix well by vortexing. The 0 pg/mL standard 
(Background) will be Assay Buffer. 
 







Standard Concentration (pg/ 
mL) 
Volume of Deionized Water to 
Add 
Volume of Standard to Add 
10,000 250 μL 0 
2,000 200 μL 50 μL of 10,000 pg/mL 
400 200 μL 50 μL of 2000 pg/mL 
80 200 μL 50 μL of 400 pg/mL 
16 200 μL 50 μL of 80 pg/mL 
3.2 200 μL 50 μL of 60 pg/mL 
 
Immunoassay Procedure 
Before beginning the assay, allow all reagents to warm to room temperature (20-25°C) 
before use in the assay. If using a filter plate, set the filter plate on a plate holder. To begin the 
assay, add 200 μL of Wash Buffer into each well of the plate. Seal and mix on a plate shaker for 
10 minutes at room temperature. Then, decant Wash Buffer and remove the residual amount 
from all wells by inverting the plate and tapping it smartly onto absorbent towels several times. 
Following this, add 25 μL of each Standard or Control into the appropriate wells. Assay Buffer 
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should be used for 0 pg/mL standard (Background). Then add 25 μL of Assay Buffer to the 
sample wells. Add 25 μL of appropriate matrix solution (from initial cell culture) to the 
background, standards, and control wells. Use proper control culture medium as the matrix 
solution. Then add 25 μL cell culture sample into the appropriate sample wells, vortex mixing 
bottle, and add 25μL beads to each well. Following this, seal the plate with a plate sealer and 
cover with foil. Incubate with agitation on a plate shaker overnight at 4°C or 2 hours at room 
temperature, preferably overnight. Gently remove well contents and wash plate two times by 
following directions in the plate washing section below. Allow to warm to room temperate and 
add 25 μL of Detection Antibodies into each well. Seal, cover with foil and incubate with 
agitation on a plate shaker for 1 hour at room temperature (20-25°C). Do not aspirate after 
incubation. Add 25 μL Streptavidin-Phycoerythrin to each well containing the 25 μL of 
Detection Antibodies. Seal, cover with foil and incubate with agitation on a plate shaker for 1 
hour at room temperature (20-25°C). Gently remove well contents and wash plate two times by 
following directions in the plate washing section below. Add 150 μL of Sheath Fluid to all wells 
and resuspend the beads on a plate shaker for 5 minutes. Run plate on Luminex 200, HTS (High 
Throughput Screening), FLEXMAP 3D® or MAGPIX® with xPONENT® software and save 
and analyze the Median Fluorescent Intensity (MFI) data using a 5-parameter logistic or spline 
curve-fitting method for calculating cytokine/chemokines concentrations in samples. For diluted 
samples, multiply the calculated concentration by the dilution factor. 
Plate Washing 
To wash the plates, use a solid plate with a handheld magnet. Rest the plate on the 
magnet for 60 seconds to allow complete settling of magnetic beads. Remove well contents by 
gently decanting the plate in an appropriate waste receptacle and gently tapping on absorbent 
 17 
pads to remove residual liquid. Wash plate with 200 μL of Wash Buffer by removing plate from 
magnet. Add wash buffer, shake for 30 seconds, reattach to magnet, allow beads to settle for 60 
seconds, remove well contents as previously described after each wash twice, and repeat 
accordingly to assay procedure. 
Data Analysis 
Results of Luminex assays were analyzed and visually represented through the creation 
of heatmaps in MATLAB. This heatmaps were coded to provide a gradient scale of fold change 
in order to indicate lower expression, higher expression, or no change in expression of a given 
cytokine or chemokine. Values for controls (immature dendritic cells) were compared to 
treatment groups, such as mature, tolerogenic, PEG-4MAL-IL-10-treated, or hydrogel-modified 
dendritic cells. The ratio between the two was plotted on the heatmap. Sample MATLAB code is 














 The following contains results of cytokine and chemokine analysis assays conducted on 
murine dendritic cell supernatant samples following encapsulation in hydrogels. The supernatant 
was obtained from the initial cell culture conducted by other members of the lab after removing 
cells using a filter plate. Testing was then conducted on the remnants of the sample. Data was 
obtained from Luminex machine quantification and visual heatmap representations were coded 
using MATLAB. 
In this study, cytokine and chemokine expression in treated dendritic cells will be 
compared to that of immature dendritic cells, which serve as a baseline. Levels seen in immature 
dendritic cells will be used to determine whether a certain cytokine and chemokine has increased 
or decreased with a given treatment. The linear range is first obtained in order to determine the 
optimal concentration of supernatant to diluent across all cytokines being tested. Figures 3, 4, 
and 5 depicts how results are displayed in heatmaps using fold changes. “Fold change” is defined 
as the ratio of each individual cytokine or chemokine between immature dendritic cells and 
treated cells. 
Pro-inflammatory cytokines of interest included TNF-alpha, IL-1alpha, IL-1beta, IL-6, 
IL-12beta, IL-8, and IFN-gamma, and anti-inflammatory cytokines of interest included IL-4, IL-
5, and IL-10. Pro-inflammatory chemokines of interest included MCP-1. Additional cytokines of 
interest include: IL-1R α, MIP-1 α, IL-12p70, and RANTES. 
 






Figure 3 presents a controls fold change between immature dendritic cell cytokine and 
chemokine expression levels and those of experimental murine cells. These cells are compared to 
tolerogenic and mature dendritic cells in order to establish a baseline expression level for the 
cytokines and chemokines being observed. Mature dendritic cells expressed noticeably higher 
levels of inflammatory cytokines as compared to tolerogenic ones – exceptions to this include 
IL-4 and IL-10, both anti-inflammatory cytokines, as well as GM-CSF, a modulator of stem cells 
to differentiate cells involved in innate (non-specific) immune response.30 All fold changes for 
previously noted cytokines of interest were significantly different between mature dendritic cells 
and immature dendritic cells, with the exception of IL-4. 
 
Figure 3. Controls fold change between iDC levels and those of experimental murine cells: tDCs 
and mDCs. Untreated tDCs and mDCs are compared to iDC expression levels as a baseline. The 
scale of colors is indicated as per the following: blue (low change) to white (moderate change) to 
red (high change). The baseline for comparison is immature dendritic cell cytokine and 
chemokine expression. For all cytokines of interest except IL-4, all fold changes between mature 
dendritic cells and immature dendritic cells were significant with P < 0.05. 
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Figure 4 depicts the PEG-4MAL-IL-10 fold change between untreated iDC levels and 
those of experimental mouse cells. Immature dendritic cells are treated with one of the 
following: IL-10, thiolated IL-10 (S-IL-10), PEGylated and thiolated IL-10 (PEG IL-10), or PEG 
(polymer without IL-10). 
 
 
Figure 4. PEG-4MAL-IL-10 fold change between untreated iDC levels and those of 
experimental mouse cells: iDCs treated with PEG and/or IL-10. The expression of IL-10 in the 
DCs were observed after being modified in different ways (S-IL10: IL-10 with thiolation, PEG 
IL-10: PEGylated and thiolated, PEG: polymer without IL-10). 
 
 Finally, Figure 5 presents results of observing dendritic cells encapsulated in hydrogels 
with varying polymer densities. This sought to understand the gel stiffness within the scaffold 
and its corresponding effect on dendritic cells. Phenotype, secreted molecules, and morphology 
of the cells were further pursued, but only for 3.5 weight percent and 4.5 weight percent only. 
This was due to the fact that dendritic cells in scaffolds of higher weight percentages (6.0% and 




Figure 5. Hydrogel wt% fold change between untreated iDC levels and those of experimental 
murine cells: iDCs in 3.5, 4.5, 6.0, or 10.0 wt% hydrogel. DCs encapsulated in hydrogels with 
varying polymer densities were observed to see the effect of gel stiffness in scaffold on DCs. 
Phenotype, secreted molecules, and morphology of the cells were then investigated. Only 3.5 
wt% and 4.5 wt% were viable as cells in higher wt% (6.0% and 10.0%) died due to gel being too 
stiff. 
 
In investigating the fold change between controls, many of the cytokine and chemokine 
expressions associated with inflammation were highly expressed in mature dendritic cells, while 
those involved with anti-inflammatory responses were not. Tolerogenic dendritic cells, 
conversely, did not present high inflammatory cytokine levels. A particularly high expression of 
IL-10, an anti-inflammatory cytokine, was observed in tDCUnk2, which is representative of the 
tolerogenic phenotype. In regard to the PEG-4MAL-IL-10 results, a notable increase in 
expression occurred in in IL-10 for the iDC + PEG-IL-10 sample. The expression of IL-10, an 
anti-inflammatory cytokine, was increased across all four modifications tested, but particularly 
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so with PEGylation and thiolation, which suggests this may be the most potent modification to 
elicit IL-10 expression. 
In the hydrogel weight percent analysis, IL-4 expression was consistently elevated, across 
all weight percent samples with the exception of iDC in 4.5 weight percent gel B, which 
exhibited a slightly less extreme increase. IL-4 is a critical cytokine involved in anti-
inflammatory responses as well as the promotion of the alternative activation of macrophages 
into M2 cells. Additionally, there was a significant increase in IL-12p70 expression within the 
iDC in 10.0 wt% gel C sample, and a slight increase in IL-3 within the iDC in 3.5 wt% gel C 
sample. IL-12p70 is involved in the regulation of T cell responses, while IL-3 stimulates 
multipotential hematopoietic progenitors, as well as lineage-committed cells.31 
While the assay gives a comprehensive visualization of cytokine expression via 
quantification of their secretory profiles, specific pro-inflammatory cytokines of interest included 
TNF-alpha, IL-1alpha, IL-1beta, IL-6, IL-12beta, IL-8, and IFN-gamma, and anti-inflammatory 
cytokines of interest included IL-4, IL-5, and IL-10. Pro-inflammatory chemokines of interest 
included MCP-1. Additional cytokines of interest include: IL-1R α, MIP-1 α, IL-12p70, and 










With some notable exceptions, the majority of cytokine and chemokine expressions in 
experimental cell groups compared to baseline immature dendritic cell expression levels were 
highly indicative of whether the dendritic cell was of a mature or tolerogenic phenotype. A less 
extreme response for the tolerogenic dendritic cells may likely be due to the fact that there is no 
antigen present to truly induce the immune response, so the mature dendritic cells are not 
secreting significant amounts of cytokines and chemokines that would require an anti-
inflammatory response to counterbalance it. 
With regard to the PEG-4MAL-IL-10 fold change between untreated immature dendritic 
cell levels and those of experimental mouse cells, it seems possible that PEGylation and 
thiolation confer a synergistic effect on IL-10 expression, or simply that PEGylation is more 
efficacious than thiolation. Further experimentation would need to be conducted with PEGylated 
IL-10 alone in order to distinguish the effects of each modification. 
The remaining samples generally exhibited slight increases in cytokine and chemokine 
expression, including those specified earlier as cytokines and chemokines of interest, with 
greater degrees of increase observed with higher weight percent hydrogel. The significant and 
consistent increase of IL-4 in the hydrogel weight percent analysis across all samples raises an 
interesting avenue of whether the hydrogel qualities potentially contributes towards anti-
inflammatory activity. This may be a result of the material comprising the hydrogel. M2 
macrophages, promoted by IL-4, encourage vessel maturation and tissue regeneration, 
suggesting that the hydrogel does encourage dendritic cell viability, functionality, and 
compatibility. This is additionally supported due to being coupled with low expression seen in 
pro-inflammatory cytokines. That being said however, cells in scaffolds of higher weight 
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percentages (6.0% and 10%) died, indicating these scaffolds’ weight were not compatible with 
the growth of dendritic cells. 
Despite the trends these data show, these results are preliminary – replications of these 
experiments and assays will need to be completed in order to confirm the cytokine and 
chemokine response. Additional experimental runs with murine samples can aid in establishing 
statistical significance for the results presented. Solidifying the dendritic cell response can aid to 
inform development and design of hydrogels for maximal dendritic cell compatibility, viability, 
and functionalization. Due to unforeseen difficulties with human dendritic cell culture, gold 
nanoparticle analysis was unable to be completed for inclusion in this thesis. These assays will 
need to be completed again upon achievement of AuNP treatment on human dendritic cells. The 
continuation of this work is paramount in order to identify how AuNPs can be developed to elicit 













Conclusion and Future Work 
These results indicate that generally, IL-10 expression increased with the four tested IL-
10 modification. Similar results of increased cytokine and chemokine secretion overall were 
observed with a corresponding increase in the weight percent of hydrogel, with limits of 6.0%, as 
cell death was observed at 6.0% and 10.0%. However, further research should be done to see 
whether the observed cytokine and chemokine response is consistent upon treatment of varying 
hydrogel modifications. By optimizing the hydrogel to function with dendritic cells, this 
technology can be leveraged to improve the viability, cellular response, and localization of 
dendritic cells that are delivered to patients for the use of amelioration of autoimmune disease 
such as EAE or MS. 
Determining the specific cytokine and chemokine response of dendritic cells, as well as 
what resulting cell phenotype is expressed, are critical to nanoparticle design and application 
within immunotherapy. Additionally, a wider range of nanoparticle concentrations can be 
investigated to fully establish cytotoxicity thresholds. Finally, the methods and data analysis used 
in this study will need to be applied to the AuNP treated-dendritic cells in order to ascertain their 
optimal design. By optimizing AuNP characteristics and conducting studies to continue assessing 
cytotoxicity and internalization of AuNPs in dendritic cells, greater clarity of the effect of 
AuNPs on the body can be obtained. This information can then subsequently be used in 
engineering and optimizing AuNP treatments for immunotherapeutic application and the creation 
of personalized immune responses. In doing so, the ultimate application of these technologies 
towards personalized medicine can work towards being achieved.  
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Figure A1. Sample MATLAB code used in data analysis. 
 
